Negative regulation by HLA-DO of MHC class II-restricted an tigen processing

Science

Volumn 278, Issue 5335, 1997, Pages 108-109

  Denzin, Lisa K ^a   Sant'Angelo, Derek B ^a   Hammond, Craig ^a   Surman, Michael J ^a   Cresswell, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; B LYMPHOCYTE ANTIGEN; H 2O ANTIGEN; H-2O ANTIGEN; H2 M ANTIGENS; H2-M ANTIGENS; HLA ANTIGEN CLASS 2; HLA D ANTIGEN; HLA DMB; HLA DO ANTIGENS; HLA DR3 ANTIGEN; HLA-DMB; HLA-DO ANTIGENS; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CONFORMATIONAL TRANSITION; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; AMINO ACID SEQUENCE; B LYMPHOCYTE; CELL CULTURE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; INVARIANT CHAIN; METABOLISM; MOLECULAR GENETICS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HLA-DR3 ANTIGEN; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; T-LYMPHOCYTES; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031551492     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. P. Cresswell, Cell 84, 505 (1996); P. R. Wolf and H. L. Ploegh, Annu. Rev. Cell Dev. Biol. 11, 267 (1995); P. Cresswell, Annu. Rev. Immunol. 12, 259 (1994).
2. P. Cresswell, Cell 84, 505 (1996); P. R. Wolf and H. L. Ploegh, Annu. Rev. Cell Dev. Biol. 11, 267 (1995); P. Cresswell, Annu. Rev. Immunol. 12, 259 (1994).
3. P. Cresswell, Cell 84, 505 (1996); P. R. Wolf and H. L. Ploegh, Annu. Rev. Cell Dev. Biol. 11, 267 (1995); P. Cresswell, Annu. Rev. Immunol. 12, 259 (1994).
4. J. M. Riberdy, J. R. Newcomb, M. J. Surman, J. A. Barbosa, P. Cresswell, Nature 360, 474 (1992); A. Sette et al., Science 258, 1801 (1992).
5. J. M. Riberdy, J. R. Newcomb, M. J. Surman, J. A. Barbosa, P. Cresswell, Nature 360, 474 (1992); A. Sette et al., Science 258, 1801 (1992).
6. P. J. Peters, J. J. Neefjes, V. Oorschot, H. L. Ploegh, H. J. Geuze, Nature 349, 669 (1991); S. Amigorena, J. R. Drake, P. Webster, I. Mellman, ibid. 369, 113 (1994); Y. Qiu, X. Xu, A. Wandinger-Ness, D. P. Dalke, S. K. Pierce, J. Cell Biol. 125, 595 (1994); A. Tulp, D. Verwoerd, B. Dobberstein, H. L. Ploegh, J. Pieters, Nature 369, 120 (1994); M. A. West, J. M. Lucocq, C. Watts, ibid., p. 147.
7. P. J. Peters, J. J. Neefjes, V. Oorschot, H. L. Ploegh, H. J. Geuze, Nature 349, 669 (1991); S. Amigorena, J. R. Drake, P. Webster, I. Mellman, ibid. 369, 113 (1994); Y. Qiu, X. Xu, A. Wandinger-Ness, D. P. Dalke, S. K. Pierce, J. Cell Biol. 125, 595 (1994); A. Tulp, D. Verwoerd, B. Dobberstein, H. L. Ploegh, J. Pieters, Nature 369, 120 (1994); M. A. West, J. M. Lucocq, C. Watts, ibid., p. 147.
8. P. J. Peters, J. J. Neefjes, V. Oorschot, H. L. Ploegh, H. J. Geuze, Nature 349, 669 (1991); S. Amigorena, J. R. Drake, P. Webster, I. Mellman, ibid. 369, 113 (1994); Y. Qiu, X. Xu, A. Wandinger-Ness, D. P. Dalke, S. K. Pierce, J. Cell Biol. 125, 595 (1994); A. Tulp, D. Verwoerd, B. Dobberstein, H. L. Ploegh, J. Pieters, Nature 369, 120 (1994); M. A. West, J. M. Lucocq, C. Watts, ibid., p. 147.
9. P. J. Peters, J. J. Neefjes, V. Oorschot, H. L. Ploegh, H. J. Geuze, Nature 349, 669 (1991); S. Amigorena, J. R. Drake, P. Webster, I. Mellman, ibid. 369, 113 (1994); Y. Qiu, X. Xu, A. Wandinger-Ness, D. P. Dalke, S. K. Pierce, J. Cell Biol. 125, 595 (1994); A. Tulp, D. Verwoerd, B. Dobberstein, H. L. Ploegh, J. Pieters, Nature 369, 120 (1994); M. A. West, J. M. Lucocq, C. Watts, ibid., p. 147.
10. P. J. Peters, J. J. Neefjes, V. Oorschot, H. L. Ploegh, H. J. Geuze, Nature 349, 669 (1991); S. Amigorena, J. R. Drake, P. Webster, I. Mellman, ibid. 369, 113 (1994); Y. Qiu, X. Xu, A. Wandinger-Ness, D. P. Dalke, S. K. Pierce, J. Cell Biol. 125, 595 (1994); A. Tulp, D. Verwoerd, B. Dobberstein, H. L. Ploegh, J. Pieters, Nature 369, 120 (1994); M. A. West, J. M. Lucocq, C. Watts, ibid., p. 147.
11. L. K. Denzin and P. Cresswell, Cell 82, 155 (1995).
12. M. A. Sherman, D. A. Weber, P. E. Jensen, Immunity 3, 197 (1995); V. S. Sloan et al., Nature 375, 802 (1995); D. A. Weber, B. D. Evavold, P. E. Jensen, Science 274, 618 (1996).
13. M. A. Sherman, D. A. Weber, P. E. Jensen, Immunity 3, 197 (1995); V. S. Sloan et al., Nature 375, 802 (1995); D. A. Weber, B. D. Evavold, P. E. Jensen, Science 274, 618 (1996).
14. M. A. Sherman, D. A. Weber, P. E. Jensen, Immunity 3, 197 (1995); V. S. Sloan et al., Nature 375, 802 (1995); D. A. Weber, B. D. Evavold, P. E. Jensen, Science 274, 618 (1996).
15. L. K. Denzin, C. Hammond, P. Cresswell, J. Exp. Med. 184, 2153 (1996).
16. H. Kropshofer, S. O. Arndt, G. Moldenhauer, G. J. Hammerling, A. B. Vogt, Immunity 6, 293 (1997).
17. M. Liljedahl et al., EMBO J. 15, 4817 (1996).
18. C. T. Wake and R. A. Flavell, Cell 42, 623 (1985); L. Karlsson, C. D. Surh, J. Sprent, P. A. Peterson, Nature 351, 485 (1991).
19. C. T. Wake and R. A. Flavell, Cell 42, 623 (1985); L. Karlsson, C. D. Surh, J. Sprent, P. A. Peterson, Nature 351, 485 (1991).
20. C. Tonnelle, R. DeMars, E. O. Long, EMBO J. 4, 2839 (1985).
21. D. C. Douek and D. M. Altman, Int. Immunol. 9, 355 (1997).
22. J. Trowsdale and A. Kelly, EMBO J. 4, 2231 (1985).
23. L. K. Denzin, N. F. Bobbins, C. Carboy-Newcomb, P. Cresswell, Immunity 1, 595 (1994).
24. 10 Raji cells was purified with a MaP.DMB-c affinity column (4). The peak fractions were pooled, and the DM-DO and DM complexes were fractionated by gel filtration with a Superose6 FPLC column (Pharmacia) equilibrated in 50 mM sodium acetate, 100 mM NaCl, 0.6% CHAPS (Pierce) (pH 5.0) at a flow rate of 0.4 ml/min. The presence of DM and DM-DO complexes in the fractions was determined by ELISA, and the peak fractions containing DM-DO complexes (19 to 21) were pooled and used in the subsequent experiments as DM-DO complexes. For the ELISA, polystyrene wells (Nunc-Immuno Plate MaxiSorb) were coated overnight at 4°C with 50 μl of the DM-specific mAb, MaP.DM2 (C. Hammond, in preparation), washed with phosphate-buffered saline (PBS) containing 0.01% Tween-20 (PBS-T), and masked for 30 min with PBS-T plus 1% bovine serum albumin (BSA). Samples containing DM or DM-DO complexes were incubated for 1 hour at room temperature, the wells were washed, and R.DOB/c or R.DMB/c (10 μg/ml) was added. Complexes were detected with horseradish peroxidase-labeled mouse anti-rabbit immunoglobulin G and Turbo-TMB (Pierce). We determined the percentage of remaining free DM in the DM-DO pool by first removing the DO (and DM-DO) by multiple rounds of immunoprecipitation with either R.DOB/c or a control antiserum and then determining the amount of free DM remaining in the immunoprecipitation supernatants by ELISA.
25. F. Sanderson, C. Thomas, J. Neefjes, J. Trowsdale, Immunity 4, 87 (1996).
26. L. K. Denzin and P. Cresswell, unpublished data.
27. HLA-DR1 and -DR4 αβCLIP complexes were purified from T2.DR1 and T2.DR4 cells as described (4) with L243 (T2.DR4) or CerCLIP.1 (T2.DR1) affinity columns. For the DM-mediated peptide-exchange assay, DM or DM-DO preparations, matched for a DM concentration of 20 ng by ELISA, were incubated with ∼10,000 cpm of radiolabeled DR1 or DR4 αβCLIP complexes and biotinylated HAp peptide (KYVKQNTLKATK-biotin) in 20 mM tris, 130 mM NaCl (pH 7.4) containing 0.6% CHAPS (Pierce). The pH was adjusted to 5.0 by the addition of 1 M acetic acid, and the samples were incubated at 37°C for the times indicated in Fig. 3. After neutralization, the HAp-class II complexes were immunoprecipitated with streptavidin-agarose beads (Pierce) and the samples were separated by SDS-PAGE. The percentage of peptide-loaded class II molecules was quantitated by image analysis with a BioRad GS-525 Molecular imager.
28. D. Eckels et al., Immunogenetics 19, 409 (1984); J. Rothbard et al., Cell 52, 515 (1988).
29. D. Eckels et al., Immunogenetics 19, 409 (1984); J. Rothbard et al., Cell 52, 515 (1988).
30. R. R. Avva and P. Cresswell, Immunity 1, 63 (1994).
31. V. Steimle, L. A. Otten, M. Aufferey, B. Mach, Cell 75, 135 (1993).
32. We cotransfected class II-negative CEM cells with CIITA-pcDNAI/Amp and pMCFR-Neo (13) at a ratio of 10:1 using previously described conditions [B. K. Sadasivan, A. Cariappa, G. L. Waneck, P. Cresswell, Cold Spring Harbor Symp. Quant. Biol. 55, 267 (1995)]. Clones resistant to geneticin were screened for expression of cell surface class II by flow cytometric analysis with the DR-specific mAb L243 [L. A. Lampson and R. Levy, J. Immunol. 125, 293 (1980)]. Positive clones were subcloned by limiting dilution, and the clone with the highest class II expression was used for subsequent DO transfection.
33. We cotransfected class II-negative CEM cells with CIITA-pcDNAI/Amp and pMCFR-Neo (13) at a ratio of 10:1 using previously described conditions [B. K. Sadasivan, A. Cariappa, G. L. Waneck, P. Cresswell, Cold Spring Harbor Symp. Quant. Biol. 55, 267 (1995)]. Clones resistant to geneticin were screened for expression of cell surface class II by flow cytometric analysis with the DR-specific mAb L243 [L. A. Lampson and R. Levy, J. Immunol. 125, 293 (1980)]. Positive clones were subcloned by limiting dilution, and the clone with the highest class II expression was used for subsequent DO transfection.
34. C. H. Chang, J. D. Fontes, M. Peterlin, R. A. Flavell, J. Exp. Med. 180, 1367 (1994); W. Reith, V. Steimle, B. Mach, Immunol. Today 16, 539 (1995); B. Mach, V. Steimle, E. Martinez-Soria, W. Reith, Annu. Rev. Immunol. 14, 301 (1996).
35. C. H. Chang, J. D. Fontes, M. Peterlin, R. A. Flavell, J. Exp. Med. 180, 1367 (1994); W. Reith, V. Steimle, B. Mach, Immunol. Today 16, 539 (1995); B. Mach, V. Steimle, E. Martinez-Soria, W. Reith, Annu. Rev. Immunol. 14, 301 (1996).
36. C. H. Chang, J. D. Fontes, M. Peterlin, R. A. Flavell, J. Exp. Med. 180, 1367 (1994); W. Reith, V. Steimle, B. Mach, Immunol. Today 16, 539 (1995); B. Mach, V. Steimle, E. Martinez-Soria, W. Reith, Annu. Rev. Immunol. 14, 301 (1996).
37. C. H. Chang and R. A. Flavell, J. Exp. Med. 181, 765 (1995); I. Kern, V. Steimle, C. A. Siegrist, B. Mach, Int. Immunol. 7, 1295 (1995); C. H. Chang, S. C. Hong, C. C. Hughes, C. A. Janeway Jr., R. A. Flavell, ibid., p. 1515.
38. C. H. Chang and R. A. Flavell, J. Exp. Med. 181, 765 (1995); I. Kern, V. Steimle, C. A. Siegrist, B. Mach, Int. Immunol. 7, 1295 (1995); C. H. Chang, S. C. Hong, C. C. Hughes, C. A. Janeway Jr., R. A. Flavell, ibid., p. 1515.
39. C. H. Chang and R. A. Flavell, J. Exp. Med. 181, 765 (1995); I. Kern, V. Steimle, C. A. Siegrist, B. Mach, Int. Immunol. 7, 1295 (1995); C. H. Chang, S. C. Hong, C. C. Hughes, C. A. Janeway Jr., R. A. Flavell, ibid., p. 1515.
40. DOA was amplified by PCR from a Raji cDNA library with primers specific for the 5′ end (5′-TCCCCC-GGGTACCGCCACCATGGCCCTCAGAGCAGGGCTG-3′) and 3′ end (5′-TCCAGTGTCCCCAGGTAATGATCGATGG-3′). The resulting PCR product was cloned into pCR2.1 (Invitrogen), sequenced, and subcloned into the eukaryotic expression vector pMCFR-PAC (13) to generate pMCFR-PAC/ DOA. CEM.CIITA cells were transfected with pM-CFR-PAC/DOA and pDOB#163 (10) at a ratio of 1:10, PMCFR-PAC/DOA alone, or empty vector alone as described (13). Clones resistant to puromycin were screened for DO expression by immunofluorescence with R.DOB/c. Two of the positive cell lines (CEM.CIITA.DO-1 and CEM.CIITA.DO-2) were chosen and used for subsequent experiments. OEM.CIITA-DOA cells were screened for DOA expression by RT-PCR analysis and CEM. CIITA. Vector-only cells were isolated by resistance to puromycin.
41. D. B. Sant'Angelo, unpublished data.
42. CEM.CIITA.DO-1 cells were mixed at a ratio of 3:1 with untransfected CEM.CIITA cells and processed for immunofluorescence as described [N. F. Robbins, C. Hammond, L. Denzin, M. Pan, P. Cresswell, Hum. Immunol. 45, 13 (1996)] with the following modifications. After fixation of the cells on coverslips, they were treated with permeabilization solution [PBS containing 5% fetal bovine serum, 1% BSA, and saponin (15 μg/ml; Sigma)], 10 mM glycine, 10 mM Hepes (pH 7.4) for 15 min at room temperature, and the coverslips were placed in a 20-μl drop of a solution of R.DOB/c (50 μg/ml) in permeabilization solution for 30 min. The coverslips were then washed three times in permeabilization solution and treated with sequential rounds of Cer-CLIP.1 or MaP.DM1 (C. Hammond, in preparation) and secondary antibodies as described above, except that the saponin concentration was increased to 500 μg/ml. After extensive washing, the coverslips were mounted onto slides with Mowiol 4-88 solution (Calbiochem).
43. CEM.CIITA.DO-1 cells were mixed at a ratio of 3:1 with untransfected CEM.CIITA cells and processed for immunofluorescence as described [N. F. Robbins, C. Hammond, L. Denzin, M. Pan, P. Cresswell, Hum. Immunol. 45, 13 (1996)] with the following modifications. After fixation of the cells on coverslips, they were treated with permeabilization solution [PBS containing 5% fetal bovine serum, 1% BSA, and saponin (15 μg/ml; Sigma)], 10 mM glycine, 10 mM Hepes (pH 7.4) for 15 min at room temperature, and the coverslips were placed in a 20-μl drop of a solution of R.DOB/c (50 μg/ml) in permeabilization solution for 30 min. The coverslips were then washed three times in permeabilization solution and treated with sequential rounds of Cer-CLIP.1 or MaP.DM1 (C. Hammond, in preparation) and secondary antibodies as described above, except that the saponin concentration was increased to 500 μg/ml. After extensive washing, the coverslips were mounted onto slides with Mowiol 4-88 solution (Calbiochem).
44. M. Ponzoni, F. Guarnaccia, M. V. Corrias, P. Cornaglia-Ferraris, Int. J. Cancer 55, 817 (1993).
45. Reviewed in D. C. Parker, Annu. Rev. Immunol. 11, 331 (1993).
46. C. D. Surh et al., J. Exp. Med. 176, 495 (1992).
47. J. F. Katz, C. Stebbins, E. Appella, A. J. Sant, ibid. 184, 1747 (1996).
48. Protein immunoblot analysis was done as described [P. J. Lehner, J. T. Karttunen, G. W. G. Wilkinson, P. Cresswell, Proc. Natl. Acad. Sci. U.S.A. 94, 6904 (1997)].
49. C. Hammond and A. Helenius, J. Cell Biol. 126, 41 (1994).
50. A. E. Berger, J. E. Davis, P. Cresswell, Hybridoma 1, 87 (1982).
51. Metabolic labeling of CEM.CIITA transfectants and affinity purifications were done as described (4, 13).
52. We thank C. Doyle, J. Brogdon, and J. Blum for cell lines; E. Long and J. Fontes for cDNA clones; and N. Dometios for preparation of the manuscript. We are grateful to B. Sadasivan for producing the CEM. CIITA cell line and C. Janeway for helpful discussions. Supported by a Donaghue Fellowship (L.K.D.), a fellowship from the Cancer Research Institute (C.H.), and by NIH grant Al14579 (D.B.S.). Funding for this research is from the Howard Hughes Medical Institute and NIH grant Al23081 (P.C.).